$ALNY News

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

Alnylam Says Phase 1b Brezosiran Study Showed Dose-Dependent CSF Mutant Huntingtin Reductions, Up To 83% Individually, No Dose-Dependent Safety Signals; Pivotal Study Planned 2027 Pending Regulatory Alignment

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253

If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today

Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide

Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value?

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345

Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Alnylam Needs Stronger Amvuttra Execution To Justify More Upside